|
gptkbp:instanceOf
|
gptkb:chemical_compound
antidepressant
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:European_Union
|
|
gptkbp:ATCCode
|
N06AX22
|
|
gptkbp:CASNumber
|
138112-76-2
|
|
gptkbp:category
|
acetamides
melatonin receptor agonists
naphthalenes
serotonin receptor antagonists
|
|
gptkbp:chemicalFormula
|
C15H17NO2
|
|
gptkbp:compatibleWith
|
gptkb:Canada
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Servier_Laboratories
|
|
gptkbp:discoveredIn
|
1990s
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
agomelatine
|
|
gptkbp:IUPACName
|
N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
melatonin receptor agonist
serotonin 5-HT2C receptor antagonist
|
|
gptkbp:meltingPoint
|
108-110°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
243.3 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
increased liver enzymes
|
|
gptkbp:synonym
|
gptkb:Melitor
gptkb:Thymanax
gptkb:Valdoxan
gptkb:Agomel
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:D08402
|
|
gptkbp:bfsLayer
|
6
|